Immunogenicity and Efficacy of Insulin Glargine Biosimilar Ezelin versus Originator Insulin Glargine in Patients with Type 2 Diabetes
Tri Juli Edi Tarigan,1 Adisti Dwijayanti,2 Susie Setyowati,3 Melva Louisa4 1Division of Endocrinology and Metabolism, Department of Internal Medicine, Dr. Cipto Mangunkusumo National Referral Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; 2Department of Medical Pharmacy, F...
Guardado en:
Autores principales: | Tarigan TJE, Dwijayanti A, Setyowati S, Louisa M |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/e27ef62c838e4bd0b2b40e3c8d590d0a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Enzyme-Linked Immunosorbent Assay Method Application in the Study of Comparative Pharmacokinetics of Insulin Glargin Preparations
por: L. N. Shitov, et al.
Publicado: (2019) -
On the safety of insulin Glargine
por: Ivan Ivanovich Dedov, et al.
Publicado: (2009) -
Effect of Adding Insulin Glargine on Glycemic Control in Critically Ill Patients Admitted to Intensive Care Units: A Prospective Randomized Controlled Study
por: Nader ND, et al.
Publicado: (2020) -
Insulin glargine: pharmacokinetic and pharmacodynamic basis of clinical effect
por: Vadim Valer'evich Klimontov, et al.
Publicado: (2014) -
Modern approach to the evaluation of the pharmacokinetics and pharmacodynamics of biosimilar recombinant human insulin and insulin analogues in I phase clinical study
por: Irina A. Proskurina, et al.
Publicado: (2016)